Point72 Asset Management
NRSN icon

Point72 Asset Management’s NeuroSense Therapeutics NRSN Stock Holding History

Point72 Asset Management’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100,000
Closed -$149K – 2749
2023
Q2 		$149K Buy
+100,000
New +$175K ﹤0.01% 1484

Other funds holding NRSN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Point72 Asset Management's NRSN Position: Q3 2023 in Review

Point72 Asset Management sold out of NeuroSense Therapeutics (NRSN) in Q3 2023, closing a stake of 100,000 shares — an estimated $149K sold.

Point72 Asset Management first reported a position in NRSN in Q2 2023 and held it in 1 quarter. The position peaked at $149K in Q2 2023. 5 funds tracked by Wall St. Rank hold NRSN as of Q3 2023.

  • Point72 Asset Management reported no remaining NeuroSense Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Point72 Asset Management sold 100,000 NeuroSense Therapeutics shares in Q3 2023, an estimated $149K.
  • Point72 Asset Management first reported a position in NeuroSense Therapeutics in Q2 2023 and held it in 1 quarter.
  • Point72 Asset Management's NeuroSense Therapeutics position peaked at $149K in Q2 2023.
  • 5 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2023.

Based on Point72 Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.